Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification
Luis D Pacheco1, Richard L Berkowitz, Kenneth J Moise
1From the Divisions of Maternal Fetal Medicine and Surgical Critical Care, Departments of Obstetrics & Gynecology and Anesthesiology, The University of Texas Medical Branch at Galveston; Division of Maternal fetal Medicine, Department of Obstetrics & Gynecology, Columbia University Medical Center; Department of Obstetrics & Gynecology and Reproductive Sciences, University of Texas School of Medicine, Houston, Texas; Department of Obstetrics & Gynecology and Pediatrics, Weill Medical College of Cornell University, New York, New York; Division of Hematology-Oncology, Department of Medicine, Medical College of Wisconsin, and Platelet and Neutrophil Immunology Laboratory, BloodCenter of Wisconsin; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, The University of Texas Medical Branch at Galveston.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) management can be optimized. A new risk-stratified algorithm avoids fetal blood sampling, improving safety and individualized treatment for FNAIT.
Area of Science:
- Obstetrics and Gynecology
- Neonatology
- Immunology
Background:
- Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a leading cause of severe fetal/neonatal thrombocytopenia and newborn intracranial hemorrhage.
- Current therapy for FNAIT relies on steroids and intravenous immunoglobulins.
- Fetal blood sampling is traditionally used to monitor treatment response, despite associated risks.
Purpose of the Study:
- To propose a novel therapeutic algorithm for FNAIT management.
- To enable risk stratification and individualized treatment optimization.
- To eliminate the need for fetal blood sampling in FNAIT therapy monitoring.
Main Methods:
- Development of a risk stratification-based therapeutic algorithm.
- Individualized treatment adjustments based on patient risk.
- Exclusion of fetal blood sampling from the treatment monitoring protocol.
Main Results:
- The proposed algorithm facilitates risk stratification for FNAIT.
- Individualized treatment optimization is achieved without invasive procedures.
- The algorithm aims to mitigate risks associated with fetal blood sampling.
Conclusions:
- A non-invasive, risk-stratified algorithm can guide FNAIT therapy.
- This approach enhances safety by avoiding fetal blood sampling.
- Optimized, individualized treatment is achievable for FNAIT patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:19Rh Blood Group